US Penny Stocks To Watch In December 2024

As the U.S. market takes a breather from its post-election rally, major indices like the Dow Jones and S&P 500 are seeing slight declines while still riding high on recent record achievements. In this context, penny stocks—often smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer unique growth opportunities, especially when backed by solid financials, making them worthy of attention for investors seeking under-the-radar potential in today's market landscape.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.81715	$5.81M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.56	$2.03B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$136.98M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2421	$8.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.58	$52.47M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9597	$84.8M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.76	$413.23M	★★★★☆☆
Smith Micro Software (NasdaqCM:SMSI)	$0.825	$15.25M	★★★★★☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

iCAD (NasdaqCM:ICAD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: iCAD, Inc. provides cancer detection and therapy solutions in the United States and has a market cap of $45.59 million.

Operations: The company generates revenue from its Detection segment, which amounts to $18.94 million.

Market Cap: $45.59M

iCAD, Inc., with a market cap of US$45.59 million, is navigating the penny stock landscape by focusing on innovative cancer detection solutions. Despite being unprofitable and having an inexperienced management team with an average tenure of 1.7 years, iCAD's strategic shift towards cloud-based AI technologies presents growth potential. The recent FDA clearance of ProFound Detection Version 4.0 enhances its competitive edge in cancer detection accuracy and specificity, potentially boosting annual recurring revenue as customers upgrade to this advanced solution. Additionally, iCAD maintains a strong financial position with short-term assets exceeding liabilities and no debt burden.

• Click here to discover the nuances of iCAD with our detailed analytical financial health report.
• Explore iCAD's analyst forecasts in our growth report.

Sypris Solutions (NasdaqGM:SYPR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Sypris Solutions, Inc. provides truck components, oil and gas pipeline components, and aerospace and defense electronics primarily in North America and Mexico with a market cap of $35.91 million.

Operations: The company generates revenue from two primary segments: Sypris Electronics, contributing $66.78 million, and Sypris Technologies, accounting for $74.69 million.

Market Cap: $35.91M

Sypris Solutions, Inc., with a market cap of US$35.91 million, is navigating the penny stock sector through its dual focus on Sypris Electronics and Sypris Technologies. Recent earnings show improvement with third-quarter sales rising to US$35.66 million and a shift to net income of US$0.39 million from a loss last year. Despite this, the company remains unprofitable over the longer term, with increasing losses at 17.1% annually over five years and negative return on equity at -15.93%. However, it maintains sufficient short-term assets to cover liabilities and has an experienced board averaging 27.9 years in tenure.

• Click to explore a detailed breakdown of our findings in Sypris Solutions' financial health report.
• Understand Sypris Solutions' track record by examining our performance history report.

Enzo Biochem (NYSE:ENZ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Enzo Biochem, Inc. is a life sciences company that focuses on labeling and detection technologies for DNA to whole cell analysis both in the United States and internationally, with a market cap of approximately $56.42 million.

Operations: The company's revenue segment is derived entirely from its Products division, generating $31.91 million.

Market Cap: $56.42M

Enzo Biochem, Inc., with a market cap of US$56.42 million, operates within the life sciences sector but remains unprofitable despite generating US$31.91 million in revenue from its Products division. The company's financial health is buoyed by short-term assets of US$70 million exceeding both short and long-term liabilities, and it has more cash than debt. However, shareholders have faced dilution over the past year, and losses have increased at 22.9% annually over five years. Recent board changes include appointing Jon Couchman to strengthen governance amidst ongoing legal settlements impacting financials.

• Click here and access our complete financial health analysis report to understand the dynamics of Enzo Biochem.
• Gain insights into Enzo Biochem's past trends and performance with our report on the company's historical track record.

Next Steps

• Access the full spectrum of 709 US Penny Stocks by clicking on this link.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com